Innate Pharma (IPHA) Stock Price, News & Analysis

Company Overview

Innate Pharma is a clinical‐stage biotechnology company headquartered in Marseille, France, with additional operations in Paris and Philadelphia. Founded in 1999, the company focuses on the discovery and development of novel immunotherapies that harness the body’s innate immune system to fight cancer. By targeting key receptors on natural killer (NK) cells, macrophages and other innate immune effectors, Innate Pharma seeks to overcome resistance mechanisms and enhance anti‐tumor responses.

The company’s lead investigational candidates include monalizumab, an anti‐NKG2A checkpoint inhibitor being evaluated in combination with established therapies, and lacutamab (IPH4102), a monoclonal antibody directed against KIR3DL2 for the treatment of cutaneous T‐cell lymphomas. Additional pipeline assets such as IPH5201, IPH6401 and IPH6101 are designed to modulate other innate immune checkpoints or to engage immune cells via bi‐ and multi‐specific formats, reflecting Innate Pharma’s broader strategy to develop differentiated antibody‐based therapies.

Innate Pharma has established strategic collaborations with leading pharmaceutical partners, including AstraZeneca and Bristol Myers Squibb, to advance its programs through global clinical development and commercialization. The company’s research and manufacturing operations span Europe and North America, enabling it to conduct multi‐regional clinical trials and to leverage regulatory expertise across key markets.

Leadership at Innate Pharma combines scientific expertise and industry experience. Under the direction of Chief Executive Officer Mondher Mahjoubi and Chief Scientific Officer Philippe Pouletty, the company has grown its immuno‐oncology platform since its inception, bolstered by a board and management team with deep roots in antibody engineering, clinical development and regulatory affairs. Over two decades of innovation have positioned Innate Pharma as a pioneer in innate immunity therapeutics.

Key Stats

• Today's Range: $1.70 to $1.81
• 50-Day Range: $1.72 to $2.44
• 52-Week Range: $1.29 to $3.51
• Volume: 4,886 shs
• Average Volume: 187,900 shs
• Market Capitalization: $160.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Strong Buy

Innate Pharma Stock Analysis - MarketRank™

Innate Pharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 543rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Innate Pharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Innate Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Innate Pharma has a P/B Ratio of 15.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently increased by 17.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innate Pharma does not currently pay a dividend.

Dividend Growth

Innate Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.10% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently increased by 17.86%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Innate Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Innate Pharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innate Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.16% of the stock of Innate Pharma is held by institutions.

IPHA Stock Analysis - Frequently Asked Questions

How have IPHA shares performed this year?

Innate Pharma's stock was trading at $1.84 at the beginning of 2025. Since then, IPHA shares have decreased by 5.3% and is now trading at $1.7432.

When did Innate Pharma IPO?

Innate Pharma (IPHA) raised $80 million in an IPO on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI acted as the underwriters for the IPO.

How do I buy shares of Innate Pharma?

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Pfizer (PFE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Altimmune (ALT), Cidara Therapeutics (CDTX) and Fulcrum Therapeutics (FULC).

Company Calendar

• Today: 7/12/2025
• Next Earnings (Estimated): 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPHA
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: 33-4-30-30-30-30
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Innate Pharma: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +531.0%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 2.52
• Current Ratio: 2.60
• Quick Ratio: 2.60

Sales & Book Value

• Annual Sales: $21.77 million
• Price / Sales: 7.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 15.85

Miscellaneous

• Outstanding Shares: 92,180,000
• Free Float: 62,781,000
• Market Cap: $160.69 million
• Optionable: Not Optionable
• Beta: 0.21